Skip to main content
NCBI home page
Journal of the National Medical Association logoLink to Journal of the National Medical Association
. 2007 Jan;99(1):35–45.

Bisphosphonate therapy for women with breast cancer and at high risk for osteoporosis.

Gloria J Morris 1, Edith P Mitchell 1
PMCID: PMC2569609  PMID: 17304967

Abstract

Bisphosphonates are effective inhibitors of osteoclast activity and bone resorption, and are standard treatments for osteoporosis, hypercalcemia of malignancy, and metabolic bone disease. Bisphosphonates have also been established to effectively reduce skeletal-related events due to malignancy metastatic to bone. Bisphosphonates are now being incorporated into breast cancer treatment regimens in order to combat osteoporosis caused by ovarian suppression, chemotherapy treatment, aromatase inhibitors and the postmenopausal state itself. A large body of evidence suggests that African-American women are at higher risk for osteoporosis-related morbidity than their Caucasian counterparts. In this review, we highlight recommendations toward screening for osteoporosis in high-risk populations. We summarize the mechanisms of action of bisphosphonates in the treatment of osteoporosis and then summarize national recommendations toward incorporating the use of bisphosphonates as support for the bone health of breast cancer patients, as well as patients at high risk for osteoporosis.

Full text

PDF
35

Images in this article

36Figure 1
on p.36
39Figure 3
on p.39

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alam Neelofar M., Archer Juanita A., Lee Euni. Osteoporotic fragility fractures in African Americans: under-recognized and undertreated. J Natl Med Assoc. 2004 Dec;96(12):1640–1645. [PMC free article] [PubMed] [Google Scholar]
  2. Aloia J. F., Vaswani A., Yeh J. K., Flaster E. Risk for osteoporosis in black women. Calcif Tissue Int. 1996 Dec;59(6):415–423. doi: 10.1007/BF00369203. [DOI] [PubMed] [Google Scholar]
  3. Baum M., Buzdar A., Cuzick J., Forbes J., Houghton J., Howell A., Sahmoud T., ATAC (Arimidex, Tamoxifen Alone or in Combination) Trialists' Group Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Cancer. 2003 Nov 1;98(9):1802–1810. doi: 10.1002/cncr.11745. [DOI] [PubMed] [Google Scholar]
  4. Bekker Pirow J., Holloway Donna L., Rasmussen Amy S., Murphy Robyn, Martin Steven W., Leese Philip T., Holmes Gregory B., Dunstan Colin R., DePaoli Alex M. A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J Bone Miner Res. 2004 Mar 1;19(7):1059–1066. doi: 10.1359/JBMR.040305. [DOI] [PubMed] [Google Scholar]
  5. Bell Norman H., Bilezikian John P., Bone Henry G., 3rd, Kaur Amarjot, Maragoto Adele, Santora Arthur C., MK-063 Study Group Alendronate increases bone mass and reduces bone markers in postmenopausal African-American women. J Clin Endocrinol Metab. 2002 Jun;87(6):2792–2797. doi: 10.1210/jcem.87.6.8575. [DOI] [PubMed] [Google Scholar]
  6. Berenson J. R., Lichtenstein A., Porter L., Dimopoulos M. A., Bordoni R., George S., Lipton A., Keller A., Ballester O., Kovacs M. Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group. J Clin Oncol. 1998 Feb;16(2):593–602. doi: 10.1200/JCO.1998.16.2.593. [DOI] [PubMed] [Google Scholar]
  7. Berenson J. R., Lipton A. Use of bisphosphonates in patients with metastatic bone disease. Oncology (Williston Park) 1998 Nov;12(11):1573–1581. [PubMed] [Google Scholar]
  8. Black Dennis M., Bilezikian John P., Ensrud Kristine E., Greenspan Susan L., Palermo Lisa, Hue Trisha, Lang Thomas F., McGowan Joan A., Rosen Clifford J., PaTH Study Investigators One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis. N Engl J Med. 2005 Aug 11;353(6):555–565. doi: 10.1056/NEJMoa050336. [DOI] [PubMed] [Google Scholar]
  9. Body J-J, Diel I. J., Lichinitser M. R., Kreuser E. D., Dornoff W., Gorbunova V. A., Budde M., Bergström B., MF 4265 Study Group Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. Ann Oncol. 2003 Sep;14(9):1399–1405. doi: 10.1093/annonc/mdg367. [DOI] [PubMed] [Google Scholar]
  10. Body J. J., Diel I. J., Lichinitzer M., Lazarev A., Pecherstorfer M., Bell R., Tripathy D., Bergstrom B. Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled phase III studies. Br J Cancer. 2004 Mar 22;90(6):1133–1137. doi: 10.1038/sj.bjc.6601663. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Body Jean-Jacques. Bisphosphonates in metastatic bone disease: renal safety matters. Oncologist. 2005;10 (Suppl 1):1–2. doi: 10.1634/theoncologist.10-90001-1. [DOI] [PubMed] [Google Scholar]
  12. Body Jean-Jacques, Diel Ingo J., Bell Richard, Pecherstorfer Martin, Lichinitser Michail R., Lazarev Alexander F., Tripathy Debu, Bergström Bengt. Oral ibandronate improves bone pain and preserves quality of life in patients with skeletal metastases due to breast cancer. Pain. 2004 Oct;111(3):306–312. doi: 10.1016/j.pain.2004.07.011. [DOI] [PubMed] [Google Scholar]
  13. Body Jean-Jacques, Greipp Philip, Coleman Robert E., Facon Thierry, Geurs Filip, Fermand Jean-Paul, Harousseau Jean-Luc, Lipton Allan, Mariette Xavier, Williams Catherine D. A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases. Cancer. 2003 Feb 1;97(3 Suppl):887–892. doi: 10.1002/cncr.11138. [DOI] [PubMed] [Google Scholar]
  14. Bohannon A. D. Osteoporosis and African American women. J Womens Health Gend Based Med. 1999 Jun;8(5):609–615. doi: 10.1089/jwh.1.1999.8.609. [DOI] [PubMed] [Google Scholar]
  15. Breast International Group (BIG) 1-98 Collaborative Group. Thürlimann Beat, Keshaviah Aparna, Coates Alan S., Mouridsen Henning, Mauriac Louis, Forbes John F., Paridaens Robert, Castiglione-Gertsch Monica, Gelber Richard D. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med. 2005 Dec 29;353(26):2747–2757. doi: 10.1056/NEJMoa052258. [DOI] [PubMed] [Google Scholar]
  16. Brown Janet E., Cook Richard J., Major Pierre, Lipton Allan, Saad Fred, Smith Matthew, Lee Ker-Ai, Zheng Ming, Hei Yong-Jiang, Coleman Robert E. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J Natl Cancer Inst. 2005 Jan 5;97(1):59–69. doi: 10.1093/jnci/dji002. [DOI] [PubMed] [Google Scholar]
  17. Budman Daniel R., Calabro Anthony. Zoledronic acid (Zometa) enhances the cytotoxic effect of gemcitabine and fluvastatin: in vitro isobologram studies with conventional and nonconventional cytotoxic agents. Oncology. 2006 Apr 26;70(2):147–153. doi: 10.1159/000093006. [DOI] [PubMed] [Google Scholar]
  18. Carter G. D., Goss Alastair N. Bisphosphonates and avascular necrosis of the jaws. Aust Dent J. 2003 Dec;48(4):268–268. [PubMed] [Google Scholar]
  19. Chirgwin J. M., Guise T. A. Molecular mechanisms of tumor-bone interactions in osteolytic metastases. Crit Rev Eukaryot Gene Expr. 2000;10(2):159–178. [PubMed] [Google Scholar]
  20. Coleman Robert E., Major Pierre, Lipton Allan, Brown Janet E., Lee Ker-Ai, Smith Matthew, Saad Fred, Zheng Ming, Hei Yong Jiang, Seaman John. Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J Clin Oncol. 2005 Jun 27;23(22):4925–4935. doi: 10.1200/JCO.2005.06.091. [DOI] [PubMed] [Google Scholar]
  21. Conte PierFranco, Guarneri Valentina. Safety of intravenous and oral bisphosphonates and compliance with dosing regimens. Oncologist. 2004;9 (Suppl 4):28–37. doi: 10.1634/theoncologist.9-90004-28. [DOI] [PubMed] [Google Scholar]
  22. Coombes R. Charles, Hall Emma, Gibson Lorna J., Paridaens Robert, Jassem Jacek, Delozier Thierry, Jones Stephen E., Alvarez Isabel, Bertelli Gianfilippo, Ortmann Olaf. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med. 2004 Mar 11;350(11):1081–1092. doi: 10.1056/NEJMoa040331. [DOI] [PubMed] [Google Scholar]
  23. Cosman Felicia, Nieves Jeri, Zion Marsha, Woelfert Lillian, Luckey Marjorie, Lindsay Robert. Daily and cyclic parathyroid hormone in women receiving alendronate. N Engl J Med. 2005 Aug 11;353(6):566–575. doi: 10.1056/NEJMoa050157. [DOI] [PubMed] [Google Scholar]
  24. Cummings Steven R., Bates David, Black Dennis M. Clinical use of bone densitometry: scientific review. JAMA. 2002 Oct 16;288(15):1889–1897. doi: 10.1001/jama.288.15.1889. [DOI] [PubMed] [Google Scholar]
  25. Delmas P. D., Balena R., Confravreux E., Hardouin C., Hardy P., Bremond A. Bisphosphonate risedronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer: a double-blind, placebo-controlled study. J Clin Oncol. 1997 Mar;15(3):955–962. doi: 10.1200/JCO.1997.15.3.955. [DOI] [PubMed] [Google Scholar]
  26. Diel I. J. Antitumour effects of bisphosphonates: first evidence and possible mechanisms. Drugs. 2000 Mar;59(3):391–399. doi: 10.2165/00003495-200059030-00001. [DOI] [PubMed] [Google Scholar]
  27. Diel I. J. Bisphosphonates in the prevention of bone metastases: current evidence. Semin Oncol. 2001 Aug;28(4 Suppl 11):75–80. doi: 10.1016/s0093-7754(01)90237-4. [DOI] [PubMed] [Google Scholar]
  28. Dunford J. E., Thompson K., Coxon F. P., Luckman S. P., Hahn F. M., Poulter C. D., Ebetino F. H., Rogers M. J. Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther. 2001 Feb;296(2):235–242. [PubMed] [Google Scholar]
  29. Durie Brian G. M., Katz Michael, Crowley John. Osteonecrosis of the jaw and bisphosphonates. N Engl J Med. 2005 Jul 7;353(1):99–102. doi: 10.1056/NEJM200507073530120. [DOI] [PubMed] [Google Scholar]
  30. Eastell R., Barton I., Hannon R. A., Chines A., Garnero P., Delmas P. D. Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. J Bone Miner Res. 2003 Jun;18(6):1051–1056. doi: 10.1359/jbmr.2003.18.6.1051. [DOI] [PubMed] [Google Scholar]
  31. Epstein Solomon. The roles of bone mineral density, bone turnover, and other properties in reducing fracture risk during antiresorptive therapy. Mayo Clin Proc. 2005 Mar;80(3):379–388. doi: 10.4065/80.3.379. [DOI] [PubMed] [Google Scholar]
  32. Gordon David H. Efficacy and safety of intravenous bisphosphonates for patients with breast cancer metastatic to bone: a review of randomized, double-blind, phase III trials. Clin Breast Cancer. 2005 Jun;6(2):125–131. doi: 10.3816/CBC.2005.n.014. [DOI] [PubMed] [Google Scholar]
  33. Goss Paul E., Ingle James N., Martino Silvana, Robert Nicholas J., Muss Hyman B., Piccart Martine J., Castiglione Monica, Tu Dongsheng, Shepherd Lois E., Pritchard Kathleen I. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med. 2003 Oct 9;349(19):1793–1802. doi: 10.1056/NEJMoa032312. [DOI] [PubMed] [Google Scholar]
  34. Green J. R., Müller K., Jaeggi K. A. Preclinical pharmacology of CGP 42'446, a new, potent, heterocyclic bisphosphonate compound. J Bone Miner Res. 1994 May;9(5):745–751. doi: 10.1002/jbmr.5650090521. [DOI] [PubMed] [Google Scholar]
  35. Green Jonathan R. Bisphosphonates: preclinical review. Oncologist. 2004;9 (Suppl 4):3–13. doi: 10.1634/theoncologist.9-90004-3. [DOI] [PubMed] [Google Scholar]
  36. Guarneri Valentina, Donati Sara, Nicolini Massimiliano, Giovannelli Simona, D'Amico Roberto, Conte Pier Franco. Renal safety and efficacy of i.v. bisphosphonates in patients with skeletal metastases treated for up to 10 Years. Oncologist. 2005 Nov-Dec;10(10):842–848. doi: 10.1634/theoncologist.10-10-842. [DOI] [PubMed] [Google Scholar]
  37. Guise Theresa A., Yin Juan Juan, Mohammad Khalid S. Role of endothelin-1 in osteoblastic bone metastases. Cancer. 2003 Feb 1;97(3 Suppl):779–784. doi: 10.1002/cncr.11129. [DOI] [PubMed] [Google Scholar]
  38. Hillner Bruce E., Ingle James N., Chlebowski Rowan T., Gralow Julie, Yee Gary C., Janjan Nora A., Cauley Jane A., Blumenstein Brent A., Albain Kathy S., Lipton Allan. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol. 2003 Sep 8;21(21):4042–4057. doi: 10.1200/JCO.2003.08.017. [DOI] [PubMed] [Google Scholar]
  39. Hiraga Toru, Williams Paul J., Ueda Akimi, Tamura Daisuke, Yoneda Toshiyuki. Zoledronic acid inhibits visceral metastases in the 4T1/luc mouse breast cancer model. Clin Cancer Res. 2004 Jul 1;10(13):4559–4567. doi: 10.1158/1078-0432.CCR-03-0325. [DOI] [PubMed] [Google Scholar]
  40. Hofbauer L. C., Kühne C. A., Viereck V. The OPG/RANKL/RANK system in metabolic bone diseases. J Musculoskelet Neuronal Interact. 2004 Sep;4(3):268–275. [PubMed] [Google Scholar]
  41. Hofbauer Lorenz C., Schoppet Michael. Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases. JAMA. 2004 Jul 28;292(4):490–495. doi: 10.1001/jama.292.4.490. [DOI] [PubMed] [Google Scholar]
  42. Hoff Ana O., Gagel Robert F. Osteoporosis in breast and prostate cancer survivors. Oncology (Williston Park) 2005 Apr;19(5):651–658. [PubMed] [Google Scholar]
  43. Hortobagyi G. N., Theriault R. L., Lipton A., Porter L., Blayney D., Sinoff C., Wheeler H., Simeone J. F., Seaman J. J., Knight R. D. Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group. J Clin Oncol. 1998 Jun;16(6):2038–2044. doi: 10.1200/JCO.1998.16.6.2038. [DOI] [PubMed] [Google Scholar]
  44. Hortobagyi G. N., Theriault R. L., Porter L., Blayney D., Lipton A., Sinoff C., Wheeler H., Simeone J. F., Seaman J., Knight R. D. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group. N Engl J Med. 1996 Dec 12;335(24):1785–1791. doi: 10.1056/NEJM199612123352401. [DOI] [PubMed] [Google Scholar]
  45. Jagdev S. P., Coleman R. E., Shipman C. M., Rostami-H A., Croucher P. I. The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: evidence for synergy with paclitaxel. Br J Cancer. 2001 Apr 20;84(8):1126–1134. doi: 10.1054/bjoc.2001.1727. [DOI] [PMC free article] [PubMed] [Google Scholar]
  46. Kasperk C. H., Börcsök I., Schairer H. U., Schneider U., Nawroth P. P., Niethard F. U., Ziegler R. Endothelin-1 is a potent regulator of human bone cell metabolism in vitro. Calcif Tissue Int. 1997 Apr;60(4):368–374. doi: 10.1007/s002239900245. [DOI] [PubMed] [Google Scholar]
  47. Kessenich C. R. Osteoporosis and African-American women. Womens Health Issues. 2000 Nov-Dec;10(6):300–304. doi: 10.1016/s1049-3867(00)00065-7. [DOI] [PubMed] [Google Scholar]
  48. Kohno Norio, Aogi Kenjiro, Minami Hironobu, Nakamura Seigo, Asaga Taro, Iino Yuichi, Watanabe Toru, Goessl Carsten, Ohashi Yasuo, Takashima Shigemitsu. Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial. J Clin Oncol. 2005 Feb 28;23(15):3314–3321. doi: 10.1200/JCO.2005.05.116. [DOI] [PubMed] [Google Scholar]
  49. Lara-Smalling Agueda A., Shelton Andrea J., Douglas Tommy C., Rianon Nahid J. Osteoporosis among perimenopausal African-American women: the relationship between sources of information and levels of knowledge about osteoporosis. J Natl Black Nurses Assoc. 2004 Dec;15(2):40–47. [PubMed] [Google Scholar]
  50. Lipton A., Costa L., Ali S., Demers L. Use of markers of bone turnover for monitoring bone metastases and the response to therapy. Semin Oncol. 2001 Aug;28(4 Suppl 11):54–59. doi: 10.1016/s0093-7754(01)90233-7. [DOI] [PubMed] [Google Scholar]
  51. Lipton Allan, Small E., Saad Fred, Gleason D., Gordon David, Smith M., Rosen Lee, Kowalski M. Ortu, Reitsma Dirk, Seaman John. The new bisphosphonate, Zometa (zoledronic acid), decreases skeletal complications in both osteolytic and osteoblastic lesions: a comparison to pamidronate. Cancer Invest. 2002;20 (Suppl 2):45–54. doi: 10.1081/cnv-120014886. [DOI] [PubMed] [Google Scholar]
  52. Lipton Allan. Toward new horizons: the future of bisphosphonate therapy. Oncologist. 2004;9 (Suppl 4):38–47. doi: 10.1634/theoncologist.9-90004-38. [DOI] [PubMed] [Google Scholar]
  53. Luckey M. M., Wallenstein S., Lapinski R., Meier D. E. A prospective study of bone loss in African-American and white women--a clinical research center study. J Clin Endocrinol Metab. 1996 Aug;81(8):2948–2956. doi: 10.1210/jcem.81.8.8768857. [DOI] [PubMed] [Google Scholar]
  54. Lønning Per E., Geisler Jürgen, Krag Lars E., Erikstein Bjørn, Bremnes Yngve, Hagen Anne I., Schlichting Ellen, Lien Ernst A., Ofjord Erik S., Paolini Jolanda. Effects of exemestane administered for 2 years versus placebo on bone mineral density, bone biomarkers, and plasma lipids in patients with surgically resected early breast cancer. J Clin Oncol. 2005 Jun 27;23(22):5126–5137. doi: 10.1200/JCO.2005.07.097. [DOI] [PubMed] [Google Scholar]
  55. Mauck Karen F., Clarke Bart L. Diagnosis, screening, prevention, and treatment of osteoporosis. Mayo Clin Proc. 2006 May;81(5):662–672. doi: 10.4065/81.5.662. [DOI] [PubMed] [Google Scholar]
  56. Mudano Amy S., Casebeer Linda, Patino Fausto, Allison Jeroan J., Weissman Norman W., Kiefe Catarina I., Person Sharina, Gilbert Donna, Saag Kenneth G. Racial disparities in osteoporosis prevention in a managed care population. South Med J. 2003 May;96(5):445–451. doi: 10.1097/01.SMJ.0000053918.93363.B0. [DOI] [PubMed] [Google Scholar]
  57. Neer R. M., Arnaud C. D., Zanchetta J. R., Prince R., Gaich G. A., Reginster J. Y., Hodsman A. B., Eriksen E. F., Ish-Shalom S., Genant H. K. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001 May 10;344(19):1434–1441. doi: 10.1056/NEJM200105103441904. [DOI] [PubMed] [Google Scholar]
  58. Nelson J. B., Hedican S. P., George D. J., Reddi A. H., Piantadosi S., Eisenberger M. A., Simons J. W. Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nat Med. 1995 Sep;1(9):944–949. doi: 10.1038/nm0995-944. [DOI] [PubMed] [Google Scholar]
  59. Neville-Webbe H. L., Evans C. A., Coleman R. E., Holen I. Mechanisms of the synergistic interaction between the bisphosphonate zoledronic acid and the chemotherapy agent paclitaxel in breast cancer cells in vitro. Tumour Biol. 2006 Mar 24;27(2):92–103. doi: 10.1159/000092489. [DOI] [PubMed] [Google Scholar]
  60. Neville-Webbe Helen L., Rostami-Hodjegan Amin, Evans Catherine A., Coleman Robert E., Holen Ingunn. Sequence- and schedule-dependent enhancement of zoledronic acid induced apoptosis by doxorubicin in breast and prostate cancer cells. Int J Cancer. 2005 Jan 20;113(3):364–371. doi: 10.1002/ijc.20602. [DOI] [PubMed] [Google Scholar]
  61. Quandt Sara A., Thompson Desmond E., Schneider Diane L., Nevitt Michael C., Black Dennis M., Fracture Intervention Trial Research Group Effect of alendronate on vertebral fracture risk in women with bone mineral density T scores of-1.6 to -2.5 at the femoral neck: the Fracture Intervention Trial. Mayo Clin Proc. 2005 Mar;80(3):343–349. doi: 10.4065/80.3.343. [DOI] [PubMed] [Google Scholar]
  62. Roodman G. David. High bone turnover markers predict poor outcome in patients with bone metastasis. J Clin Oncol. 2005 Jun 27;23(22):4821–4822. doi: 10.1200/JCO.2005.02.911. [DOI] [PubMed] [Google Scholar]
  63. Roodman G. David. Mechanisms of bone metastasis. N Engl J Med. 2004 Apr 15;350(16):1655–1664. doi: 10.1056/NEJMra030831. [DOI] [PubMed] [Google Scholar]
  64. Rosen Lee S., Gordon David, Kaminski Mary, Howell Anthony, Belch Andrew, Mackey John, Apffelstaedt Justus, Hussein Mohamad A., Coleman Robert E., Reitsma Dirk J. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer. 2003 Oct 15;98(8):1735–1744. doi: 10.1002/cncr.11701. [DOI] [PubMed] [Google Scholar]
  65. Rosen Lee S., Gordon David, Tchekmedyian N. Simon, Yanagihara Ronald, Hirsh Vera, Krzakowski Maciej, Pawlicki Marek, De Souza Paul, Zheng Ming, Urbanowitz Gladys. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, Phase III, double-blind, placebo-controlled trial. Cancer. 2004 Jun 15;100(12):2613–2621. doi: 10.1002/cncr.20308. [DOI] [PubMed] [Google Scholar]
  66. Rosen Lee S., Gordon David, Tchekmedyian Simon, Yanagihara Ronald, Hirsh Vera, Krzakowski M., Pawlicki M., de Souza Paul, Zheng Ming, Urbanowitz Gladys. Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial--the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J Clin Oncol. 2003 Aug 15;21(16):3150–3157. doi: 10.1200/JCO.2003.04.105. [DOI] [PubMed] [Google Scholar]
  67. Saad Fred, Gleason Donald M., Murray Robin, Tchekmedyian Simon, Venner Peter, Lacombe Louis, Chin Joseph L., Vinholes Jeferson J., Goas J. Allen, Chen Bee. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst. 2002 Oct 2;94(19):1458–1468. doi: 10.1093/jnci/94.19.1458. [DOI] [PubMed] [Google Scholar]
  68. Shapiro C. L., Manola J., Leboff M. Ovarian failure after adjuvant chemotherapy is associated with rapid bone loss in women with early-stage breast cancer. J Clin Oncol. 2001 Jul 15;19(14):3306–3311. doi: 10.1200/JCO.2001.19.14.3306. [DOI] [PubMed] [Google Scholar]
  69. Small Eric J., Smith Matthew R., Seaman John J., Petrone Stephanie, Kowalski Mildred Ortu. Combined analysis of two multicenter, randomized, placebo-controlled studies of pamidronate disodium for the palliation of bone pain in men with metastatic prostate cancer. J Clin Oncol. 2003 Oct 27;21(23):4277–4284. doi: 10.1200/JCO.2003.05.147. [DOI] [PubMed] [Google Scholar]
  70. Tanvetyanon T., Stiff P. J. Management of the adverse effects associated with intravenous bisphosphonates. Ann Oncol. 2006 Mar 17;17(6):897–907. doi: 10.1093/annonc/mdj105. [DOI] [PubMed] [Google Scholar]
  71. Tripathy D., Lichinitzer M., Lazarev A., MacLachlan S. A., Apffelstaedt J., Budde M., Bergstrom B., MF 4434 Study Group Oral ibandronate for the treatment of metastatic bone disease in breast cancer: efficacy and safety results from a randomized, double-blind, placebo-controlled trial. Ann Oncol. 2004 May;15(5):743–750. doi: 10.1093/annonc/mdh173. [DOI] [PubMed] [Google Scholar]
  72. U.S. Preventive Services Task Force Screening for osteoporosis in postmenopausal women: recommendations and rationale. Ann Intern Med. 2002 Sep 17;137(6):526–528. doi: 10.7326/0003-4819-137-6-200209170-00014. [DOI] [PubMed] [Google Scholar]
  73. Unson Christine G., Fortinsky Richard, Prestwood Karen, Reisine Susan. Osteoporosis medications used by older African-American women: effects of socioeconomic status and psychosocial factors. J Community Health. 2005 Aug;30(4):281–297. doi: 10.1007/s10900-005-3706-3. [DOI] [PubMed] [Google Scholar]
  74. Van Poznak Catherine, Sauter Nicholas P. Clinical management of osteoporosis in women with a history of breast carcinoma. Cancer. 2005 Aug 1;104(3):443–456. doi: 10.1002/cncr.21201. [DOI] [PubMed] [Google Scholar]
  75. Vincenzi Bruno, Santini Daniele, Dicuonzo Giordano, Battistoni Fabrizio, Gavasci Michele, La Cesa Annalisa, Grilli Claudia, Virzì Vladimir, Gasparro Simona, Rocci Laura. Zoledronic acid-related angiogenesis modifications and survival in advanced breast cancer patients. J Interferon Cytokine Res. 2005 Mar;25(3):144–151. doi: 10.1089/jir.2005.25.144. [DOI] [PubMed] [Google Scholar]
  76. Vogt Ulf, Bielawski Krzysztof P., Bosse Ulrich, Schlotter Claus M. Breast tumour growth inhibition in vitro through the combination of cyclophosphamide/metotrexate/5-fluorouracil, epirubicin/cyclophosphamide, epirubicin/paclitaxel, and epirubicin/docetaxel with the bisphosphonates ibandronate and zoledronic acid. Oncol Rep. 2004 Nov;12(5):1109–1114. [PubMed] [Google Scholar]
  77. Wallace Lorraine Silver, Ballard Joyce E., Holiday David, Turner Lori W., Keenum Amy J., Pearman Cynthia M. Evaluation of decision rules for identifying low bone density in postmenopausal African-American women. J Natl Med Assoc. 2004 Mar;96(3):290–296. [PMC free article] [PubMed] [Google Scholar]
  78. Wilkins Consuelo H., Goldfeder Jason S. Osteoporosis screening is unjustifiably low in older African-American women. J Natl Med Assoc. 2004 Apr;96(4):461–467. [PMC free article] [PubMed] [Google Scholar]
  79. Winer Eric P., Hudis Clifford, Burstein Harold J., Wolff Antonio C., Pritchard Kathleen I., Ingle James N., Chlebowski Rowan T., Gelber Richard, Edge Stephan B., Gralow Julie. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol. 2004 Nov 15;23(3):619–629. doi: 10.1200/JCO.2005.09.121. [DOI] [PubMed] [Google Scholar]
  80. Woo Sook-Bin, Hellstein John W., Kalmar John R. Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med. 2006 May 16;144(10):753–761. doi: 10.7326/0003-4819-144-10-200605160-00009. [DOI] [PubMed] [Google Scholar]
  81. Woodward Julia K. L., Neville-Webbe Helen L., Coleman Robert E., Holen Ingunn. Combined effects of zoledronic acid and doxorubicin on breast cancer cell invasion in vitro. Anticancer Drugs. 2005 Sep;16(8):845–854. doi: 10.1097/01.cad.0000175582.01446.6f. [DOI] [PubMed] [Google Scholar]
  82. Yoneda T., Hashimoto N., Hiraga T. Bisphosphonate actions on cancer. Calcif Tissue Int. 2003 Jul 24;73(4):315–318. doi: 10.1007/s00223-002-0025-x. [DOI] [PubMed] [Google Scholar]

Articles from Journal of the National Medical Association are provided here courtesy of National Medical Association

RESOURCES